(For other news from the Reuters India Investment Summit, click here)
BANGALORE Nov 23 (Reuters) - Biocon Ltd, India's largest listed biotechnology company, expects to find a deep-pocketed global partner for its experimental oral insulin pill by end-March, its top executive said on Wednesday .
"We are in advanced discussions with potential partners," Biocon's Managing Director Kiran Mazumdar-Shaw told the Reuters India Investment Summit in Bangalore.
In January, Biocon had said it was looking for a partner after its oral insulin, IN-105, failed to meet the main goal of an Indian late-stage trial in patients with type-2 diabetes.
Mazumdar-Shaw, however, declined to name any potential partners.
She also said the planned IPO of its contract research organisation, Syngene, was on track.
(For summit blog: blogs.reuters.com/summits/)
(For more on the Reuters India Investment Summit, see ) (Reporting by Anand Basu, Jochelle Mendonca and Aftab Ahmed in Bangalore. Editing by Sriraj Kalluvila, Saumyadeb Chakrabarty)
Trending On Reuters
With the Nifty breaching 8,500, sentiments are again bullish. But markets have been in the 8,200-8,600 range for some time and stocks across the board do not give the required confidence except for the liquidity factor. Many frontline stocks are not participating on the upside and the core sector is in a downtrend, writes Ambareesh Baliga. Column